Center for Molecular Biology of Oral Diseases, University of Illinois at Chicago, Chicago, IL 60612, USA.
Biochimie. 2010 Nov;92(11):1587-96. doi: 10.1016/j.biochi.2010.05.011. Epub 2010 Jun 2.
Serpin family protein proteinase inhibitors regulate the activity of serine and cysteine proteinases by a novel conformational trapping mechanism that may itself be regulated by cofactors to provide a finely-tuned time and location-dependent control of proteinase activity. The serpin, antithrombin, together with its cofactors, heparin and heparan sulfate, perform a critical anticoagulant function by preventing the activation of blood clotting proteinases except when needed at the site of a vascular injury. Here, we review the detailed molecular understanding of this regulatory mechanism that has emerged from numerous X-ray crystal structures of antithrombin and its complexes with heparin and target proteinases together with mutagenesis and functional studies of heparin-antithrombin-proteinase interactions in solution. Like other serpins, antithrombin achieves specificity for its target blood clotting proteinases by presenting recognition determinants in an exposed reactive center loop as well as in exosites outside the loop. Antithrombin reactivity is repressed in the absence of its activator because of unfavorable interactions that diminish the favorable RCL and exosite interactions with proteinases. Binding of a specific heparin or heparan sulfate pentasaccharide to antithrombin induces allosteric activating changes that mitigate the unfavorable interactions and promote template bridging of the serpin and proteinase. Antithrombin has thus evolved a sophisticated means of regulating the activity of blood clotting proteinases in a time and location-dependent manner that exploits the multiple conformational states of the serpin and their differential stabilization by glycosaminoglycan cofactors.
丝氨酸蛋白酶抑制剂家族蛋白通过一种新颖的构象捕获机制来调节丝氨酸和半胱氨酸蛋白酶的活性,这种机制本身可能受到辅因子的调节,从而提供精细调节的、时间和位置依赖的蛋白酶活性控制。丝氨酸蛋白酶抑制剂抗凝血酶与其辅因子肝素和硫酸乙酰肝素一起,通过防止血液凝固蛋白酶的激活来发挥关键的抗凝作用,除非在血管损伤部位需要。在这里,我们回顾了从抗凝血酶及其与肝素和靶蛋白酶的复合物的许多 X 射线晶体结构以及肝素-抗凝血酶-蛋白酶相互作用在溶液中的突变和功能研究中得出的这种调节机制的详细分子理解。与其他丝氨酸蛋白酶抑制剂一样,抗凝血酶通过在暴露的反应中心环以及环外的变构部位呈现识别决定因素,从而对其靶血液凝固蛋白酶具有特异性。由于不利的相互作用降低了与蛋白酶的有利 RCL 和变构部位相互作用,因此在没有其激活剂的情况下,抗凝血酶的反应性受到抑制。与特定的肝素或硫酸乙酰肝素五糖结合到抗凝血酶上会诱导变构激活变化,减轻不利的相互作用并促进丝氨酸蛋白酶和蛋白酶的模板桥接。抗凝血酶因此进化出了一种复杂的方式来调节血液凝固蛋白酶的活性,这种方式利用了丝氨酸蛋白酶的多种构象状态及其与糖胺聚糖辅因子的差异稳定性。